WallStSmart

BridgeBio Pharma Inc (BBIO)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BridgeBio Pharma Inc generates 96001% more annual revenue ($713.07M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -97.0%. BBIO earns a higher WallStSmart Score of 31/100 (F).

BBIO

Avoid

31

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 6.7Quality: 5.0
Piotroski: 2/9Altman Z: -6.99

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BBIOUndervalued (+88.0%)

Margin of Safety

+88.0%

Fair Value

$636.90

Current Price

$72.44

$564.46 discount

UndervaluedFair: $636.90Overvalued

Intrinsic value data unavailable for RVMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BBIO2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
120.4%10/10

Revenue surging 120.4% year-over-year

Debt/EquityHealth
-0.9910/10

Conservative balance sheet, low leverage

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

Areas to Watch

BBIO4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-1790.0%2/10

ROE of -1790.0% — below average capital efficiency

Free Cash FlowQuality
$-223.78M2/10

Negative free cash flow — burning cash

RVMD4 concerns · Avg: 3.5/10
Price/BookValuation
16.9x4/10

Trading at 16.9x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : BBIO

The strongest argument for BBIO centers on Revenue Growth, Debt/Equity. Revenue growth of 120.4% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : BBIO

The primary concerns for BBIO are EPS Growth, Piotroski F-Score, Return on Equity.

Bear Case : RVMD

The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.

Key Dynamics to Monitor

BBIO profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

BBIO is growing revenue faster at 120.4% — sustainability is the question.

BBIO generates stronger free cash flow (-224M), providing more financial flexibility.

Bottom Line

BBIO scores higher overall (31/100 vs 24/100) and 120.4% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BridgeBio Pharma Inc

HEALTHCARE · BIOTECHNOLOGY · USA

BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. The company is headquartered in Palo Alto, California.

Visit Website →

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?